Vir Biotechnology, Inc. — Director's Dealing 2019

Oct 11, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-10

Reporting Person: SVF Endurance (Cayman) Ltd (10% Owner)
Reporting Person: SB INVESTMENT ADVISERS (UK) LTD (10% Owner)
Reporting Person: SOFTBANK VISION FUND (AIV M1) L.P. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Convertible Preferred Stock	$		Common Stock (15555555)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (6111111)		Indirect

Footnotes

F1: The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock are each convertible into Vir Biotechnology, Inc. common stock, have no expiration date and will convert into common stock automatically upon completion of the issuer's initial public offering.

F2: SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. SBIA UK is wholly owned by SoftBank Group Corp.